PR Newswire Clinical TrialsOriginal article
XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation
positivesiRNA preclinical candidate (unnamed)Positive
AI Analysis
Summary
XtalPi nominated its first siRNA preclinical candidate for IgA nephropathy nine months after program initiation. Preclinical data show subnanomolar potency with an IC50 tens of times lower than two clinical-stage reference molecules, and a single dose sustained target-protein suppression in non-human primates.
Outcome Details
Preclinical candidate nominated nine months after program initiation; subnanomolar silencing potency with IC50 tens of times lower than two clinical-stage reference molecules; single dose maintained robust target-protein suppression in non-human primates.
Importance:3/10
Sentiment:
0.50
siRNApreclinicalIgA nephropathycandidate nominationAI drug discoverynon-human primate data
Read the original article
Published by PR Newswire Clinical Trials on October 15, 2026 3:38 PM